Display Settings:

Format

Send to:

Choose Destination
Gan To Kagaku Ryoho. 2012 Nov;39(12):2095-7.

[Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer].

[Article in Japanese]

Author information

  • 1Dept. of Surgery, Osaka General Medical Center, Osaka, Japan.

Abstract

PURPOSE:

There is no standard second line regimen for metastatic or recurrent esophageal cancer. We investigated the feasibility of combination chemotherapy with Docetaxel (DOC) and Nedaplatin (CDGP) as a second-line regimen for metastatic or recurrent esophageal cancer.

MATERIALS AND METHODS:

Patients received DOC (60 mg/m2 intravenously) on day 1 and subsequently CDGP(70 mg/m2 intravenously) on day 1 of each 4-week period thereafter. We analyzed the toxicity and efficacy in 9 patients treated with combination chemotherapy with DOC and CDGP.

RESULT:

The observed Grade 3-4 toxicities were neutropenia and anemia. Three patients had stable disease and 6 patients had progressive disease. The median progression free survival and overall survival were 4.3 and 8.1 months, respectively.

CONCLUSION:

Combination chemotherapy with DOC and CDGP is considered a feasible second line regimen for metastatic or recurrent esophageal cancer.

PMID:
23267988
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Sunmedia PierOnline
    Loading ...
    Write to the Help Desk